Novo Nordisk to invest £115m in Oxford’s research

31st January 2017

Danish pharmaceutical firm Novo Nordisk partners Oxford University on ten-year collaboration to tackle type-2 diabetes.

Pharmaceutical giant Novo Nordisk has unveiled plans to invest £115m over the next ten years in a new research centre for Oxford University.

The centre, which will eventually bring together around 100 scientists, will be investigating new approaches to type-2 diabetes. The centre, which will be headed up by James Johnson of University of British Columbia, will be specifically designed to encourage collaborations between both academic and industrial scientists with the aim of sharing research across sectors.

Adam Stoten, Head of Technology Transfer (Life Sciences) at Oxford University Innovation, said:

“The decision by Novo Nordisk to invest in Oxford is another example of how the University is collaborating with industry to attract world-class companies to undertake R&D here, and how the size, quality and diversity of the Oxford biocluster continues to grow.”

For more information, click here.

Press release sign up